chrisvoncsefalvay/vaers-outcomes huggingface dataset:
some pain in shot site/Where the shot was given hurt very much; tingling down her arm, pain in her back and top of shoulder; Feel like a stinging and tingling down my arm; swollen lymph node in the back of her ear and back of her throat area; I had some pain in my back shoulder on the same side for a couple of days on the top of my shoulder; congestion of the lymph node/ most probably from the neck area to the ear; This is a spontaneous report from a contactable consumer or other non HCP (Patient). A female patient (Patient Age: 66: unit not reported) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on 03Mar2021 as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. Consumer stated, "she was just calling because she had a shot last week/last Wednesday on 03Mar2021. She did not have any major reaction, but she was having some reaction, but she wanted to (incomplete sentence). She means she have kind of read after that it sounds like it was not totally abnormal but she just wants to make sure that she won't have (incomplete sentence) you know should she definitely get the second shot. Consumer stated, "So, immediately when she got the shot (In 03Mar2021), she did feel like a stinging and tingling down her arm and she have continued to have like the actual where the shot was given hurt very much/some pain in shot site. In Mar2021, she had some pain in her back shoulder on the same side for a couple of days on the top of her shoulder and now she have got like, in the past few days she developed sort of on the same side, it feels like her lymph node was some kind of swollen in the back of her ear and back of her throat area almost like inside but not a swollen throat all on the same side where she got the vaccine, but it feels, she mean inside like she do not feel it was like externally, she feel like there was some problem with like may be like the congestion of the lymph node on that side according to her view, most probably from the neck area to the ear. Serious: No. The outcome of the events was unknown.  No follow-up attempts are possible, information about lot/batch number cannot be obtained.
Weeping eczema of toes started.Especial exacerbation began after second vaccination. Now it is crossing on fingers.; This is a spontaneous report from a contactable consumer(patient). A 64-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on an unspecified date (Lot Number: ER 8736 and expiration date was not reported) at dose 1, single and via unspecified route of administration on an unspecified date (Lot Number and expiration date were not reported) dose 2, single for covid-19 immunization. The patient medical history was not reported. Concomitant medication included nifedipine (NIFEDIPINE); hydralazine (HYDRALAZINE); rivaroxaban (XARELTO). Patient had no known allergies. The patient experienced weeping eczema of toes and exacerbation began after second vaccination and it is crossing on fingers (hospitalization) on 08Apr2021 17:00. The patient was hospitalized for 5 days. Prior to vaccination, the patient was not diagnosed with COVID-19. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient underwent lab tests and procedures which included Nasal swab: PCR test: negative on 06May2021. The events resulted in Physician or other HCP visit. No treatment was given for events. The outcome of the events was not recovered.  No follow-up attempts are possible. No further information is expected.
Covid-19; Covid-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 44-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "Covid-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) negative, notes: Tested positive 5 days after final treatment and 2 negative results; (unspecified date) negative, notes: Tested positive 5 days after final treatment and 2 negative results; (24May2022) positive, notes: Tested positive 5 days after final treatment and 2 negative results. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Adverse event: Tested positive 5 days after final treatment and 2 negative results. Anti-viral started on 15May2022 for COVID 19 Treatment and stopped on 19May2022.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
DISCOMFORT IN ARM; NOT FEELING WELL; This spontaneous report received from a patient concerned a 73 year old male. The patient's height, and weight were not reported. The patient's past medical history included: myocarditis and pericarditis in 1970. The patient was previously treated with covid-19 vaccine ad26. cov2. s(suspension for injection, route of admin not reported, batch number: 1805025 expiry: UNKNOWN) dose was not reported,1 total administered on 26-MAR-2021 to right arm for prophylactic vaccination.(Dose number in series 1). On 26-MAR-2021, the patient had discomfort in arm, and was not feeling well  which lasted a few days (events occurred on dose number in series 1).  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 211D21A expiry: UNKNOWN) dose was not reported,1 total administered on 12-NOV-2021 for prophylactic vaccination (Dose number in series 2). No adverse events reported with booster dose. No concomitant medications were reported.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from discomfort in arm, and not feeling well. This report was non-serious.
Sudden onset of loss of feeling in right arm, loss of speech, tongue hanging out of mouth,  All on right side.  Later diagnosed as a TIA.
Felt Charlie horse feeling in stomach after injection. Felt short of breath and light headed. Pulse thready and looked pale. Went to ER. Labs drawn, Chest X-ray done. Given BENADRYL IV and some MEDROL IV due to develop a rash to neck and arms.
my arm still hurts; Initial information received on 07-Dec-2022 regarding an unsolicited valid social media non-serious case received from a consumer/non-healthcare professional (hcp).  This case involves an unknown age and unknown gender patient who experienced my arm still hurts after receiving vaccine Influenza Vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received suspect Influenza Vaccine produced by unknown manufacturer (strength, formulation, route, dose: unknown) (lot number and expiry date: not reported) in unknown administration site for Flu vaccination (Influenza immunisation).  On an unknown date, the patient developed a non-serious event of my arm still hurts (pain in extremity) (unknown latency) following the administration of INFLUENZA VACCINE.  It is unknown if the patient experienced any additional symptoms/events. It is unknown if the patient had any medical history, concomitant disease or risk factor. It is unknown if there were lab data/results available.  Action taken with INFLUENZA VACCINE (INFLUENZA VACCINE) was not applicable.  It was not reported if the patient received a corrective treatment for the event (my arm still hurts).  At time of reporting, the outcome was Unknown for the event my arm still hurts.
Patient had her first Pfizer Covid shot and returned on 4/1/21 for her 2nd dose and was given Moderna. She did not experience and side effects. She just happened to notice her vaccine card with 2 diff vaccines.
Mild to moderate heart pain; This spontaneous case was reported by a consumer and describes the occurrence of ANGINA PECTORIS (Mild to moderate heart pain) in a 27-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced ANGINA PECTORIS (Mild to moderate heart pain) (seriousness criterion medically significant). At the time of the report, ANGINA PECTORIS (Mild to moderate heart pain) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       No concomitant product use was provided.  The patient got the vaccine months ago and have been getting mild to moderate heart pain since he got the vaccine. The patient had no heart pain prior.  No treatment medication was provided.  Company comment: This spontaneous case reported by a consumer concerns a 27-year-old male patient with no reported medical history who experienced the unexpected serious (medically significant) event of Angina pectoris (Mild to moderate heart pain) which occurred unknown days after administration of an unspecified dose of mRNA-1273 vaccine in COVID 19 vaccination series. No details regarding medical history, clinical course, investigations, treatment, and event outcome are provided. The benefit-risk relationship of mRNA-1273 is not affected by this report. Seriousness of the event assessed as per medical judgement.; Sender's Comments: This spontaneous case reported by a consumer concerns a 27-year-old male patient with no reported medical history who experienced the unexpected serious (medically significant) event of Angina pectoris (Mild to moderate heart pain) which occurred unknown days after administration of an unspecified dose of mRNA-1273 vaccine in COVID 19 vaccination series. No details regarding medical history, clinical course, investigations, treatment, and event outcome are provided. The benefit-risk relationship of mRNA-1273 is not affected by this report. Seriousness of the event assessed as per medical judgement.
doses administered after more than 1 temperature excursion; doses administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Apr-2021 at 11:59 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 15-Apr-2021 at 11:59 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (doses administered after more than 1 temperature excursion) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient age was reported as 55.96 years.  Concomitant products were not provided.  Batch number 044B21A underwent temperature excursion on 15-Apr-2021 with temperature 34 degrees Fahrenheit from 09 AM. This vial was moved to fridge on 06-Apr-2021 and beyond use date for the vial was reported as 09-May-2021. Product moved to clinic on 15-Apr-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a temperature monitor at every hour.  No treatment medications were reported.
Pt started experiencing loss of taste one day after his second dose of Pfizer COVID-19. Interestingly, pt had COVID-19 in November 2020 and did not have loss of smell or taste at that time. Since his second vaccine on 4/23/21, pt has not had return of taste. No other associated symptoms; pt can still smell-- with less acuity than before.
Injection side myalgia including bicep, tricep, deltoid, and pectoral.
This spontaneous report as received from a physician refers to a patient of unknown age and gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 28-JUL-2015, the patient was inadvertently vaccinated with improperly stored VARIVAX (Merck) lot # K006133, expiry date 29-APR-2016 (site, route and dose was not reported). Additional information is not expected as the reporter did not wish the further contact.
arm tingled, moved to tongue & head, felt like blacking out & airway closing;pt given epi, solumedrol, DPH, albut/atrovent, zantac, ativan, 02 IV;WBC 13.0, neutrophils 26;lymph 20;atypical lymphs 47;K 3.0;total co2 19, glucose 14.5;
Information has been received from a physician concerning a 5-year-old male with a penicillin allergy and a history of neutropenia (on 08-JAN-2005), who on 27-JAN-2005 was vaccinated in the left arm with a dose of Varivax (lot# 649846/0767P). At the time of vaccination the patient was on acyclovir for treatment of neutropenia consistent with viral EBV. On 24-APR-2006 the patient experienced shingles in the T2 dermatome. The patient did not experience a fever. Unspecified medical attention was sought and the patient was entered in the VZV identification program on 27-APR-2006. The specimen was from a lesion and the result indicated that it was vaccine strain. It was noted that there was no history of chickenpox or recent exposure to chickenpox or herpes zoster. No product quality complaint was involved. Additional information has been requested.
Face / tongue / throat swelling sensation without problems breathing or swallowing or speaking Prescription medication needed
Headache, itchy red blisters first at injection site, then over legs, arms, and back. Also, patient is experiencing hair loss approximately 1/3 of hair has been lost. Been going on since 6/28/2013 no treatment.
soft bowel movements for two days; rigors; Profound Fatigue For 36 Hours and Milder Fatigue Thereafter; Myalgias; Cramps; This is a spontaneous report from a contactable physician (patient himself). A 69-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: el0142; expiry date: unknown) intramuscular (right arm), on 06Jan2021 at 15:00, at a single dose, for COVID-19 immunization. Medical history included increased cholesterol; allergies to penicillin; and COVID-19 that started on an unspecified date (prior COVID-19 vaccination) to an unspecified date (ongoing: no). Concomitant medication included rosuvastatin calcium (CRESTOR). The patient did not receive other vaccines within four weeks prior to COVID vaccination. The vaccine was administered in the hospital. On 07Jan2021, at 06:00, the patient experienced myalgias and cramps. The next morning (08Jan2021), the patient experienced rigors. 26 hours post vaccination, he experienced profound fatigue for 36 hours which became milder fatigue thereafter. On an unspecified date, the patient experienced soft bowel movements for 2 days. The patient did not receive treatment for the events. Outcome of the events was unknown. The patient has not been tested for COVID-19 since vaccination.
Severe leg and thigh cramps and joint pain for several hours, headache, large swelling at injection site ( rash, itch, pain)
Experienced chills and fever within first 48 hours of vaccination that subsided without need for additional treatment, but in 2-7 days after dose, still experiencing ongoing muscle weakness (leg muscles in particular sometimes feel too weak to walk), lightheadedness, fatigue, swollen lymph nodes in throat.
Pt was given the Bivalent Pfizer dose for 12 years and up and patient is only 7 years old at our vaccine clinic. Mom of patient informed of error. Reports pt had some side  effects over the weekend, but experienced this with her first dose of the COVID vaccine. Mom reports patient has no symptoms today and is feeling fine. Informed our health officer of the error.
Headache; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.  On 08-Sep-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Headache). At the time of the report, HEADACHE (Headache) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   No concomitant medications were reported.  No treatment information was provided.
This spontaneous report was received from a medical assistant who referred to an unspecified number of patients of unknown demographics. No information regarding the patients' pertinent medical history, concomitant therapies and drug reactions or allergies was provided. On unknown date, the patients were vaccinated with improperly stored doses of ZOSTAVAX lot# M044220 with expiration date: 31-JAN-2018 (dose and route of administration were not reported) as prophylaxis. The sterile diluent (manufacturer unknown) used was stored properly. The doses of vaccine were stored between 6 degrees Fahrenheit (F) to 14F for 54 minutes. No previous temperature excursions were detected. Digital data logger was involved. No adverse effects were reported. No product quality complaint was involved. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1707USA006289: US-009507513-1707USA009050: US-009507513-1707USA009051: US-009507513-1707USA009052: US-009507513-1707USA009053: US-009507513-1707USA009054: US-009507513-1707USA009055: US-009507513-1707USA009056:
Post vaccination syncope within 30 seconds of administration, controlled descent to exam table without trauma or injury. Syncope with loss of bladder control. Loss of consciousness lasted for 1-2 minutes. Use of ammonia inhalants to help restore consciousness. Physical exam including neuro WNL after event. EKG sinus arrhythmia otherwise normal. Monitoring for 30 mins after patient normal and felt well. Mother instructed to watch for ALOC at home and go to ER if occurs. Mother is concerned if patient should get additional doses of menveo in the future.
Very bad headache that started on Monday night...  progressed all day on Tuesday.  I started feeling better when I woke up on Wednesday.  The pain was in the left temple.  It was also hurt to touch it.  My face and teeth also felt some pain.  On Wednesday morning, the headache started to go away but I could still feel it very slightly
Pt. came in for 3rd injection & stated that her last injection she felt dizzy, "not herself", she could not remember that day. She felt confused, SOB? all day - did not call MD or go to ER. No treatment was given.
The patient started C/O scratchy throat and nasal congestion. She is having muscle spasms in arm Tdap was given. Last night had for 7 hours. She is having occasional tingling in lower legs and today can feel in thighs. She is having back pain and neck spasms. She was seen at the Clinic on 6/8/18 for muscle spasms in neck, tinnitus of both ears and back pain. The patient states that she has all of these symptoms in the past, but not all at once of this severe. It was explained at visit that her symptoms may not be side effects. She called today wanting this to be sent.
Pain & swelling in arm on 7/16/12 fever/chills. Sent to local ER admission x 1 day given Doxycycline 100mg PO (7 days Rx).
developed sx and tested positive for covid on binax rapid antigen test 1/22/2022
high pitched squeal evening of DTP; local reaction 3" redness, warmth & sl swelling;
Vaccine given to left arm per client on 11/2/15. She began having itching on 11/3 to left arm and chest. Developed rash on 11/8 to (L) arm, (L) breast and chest, 2-3 spots to center of back. Most spots on breast. Itching/burning worse today. No blisters.
This case was reported by a lawyer and described the occurrence of neurological injury in a make subject who was vaccinated with hepatitis B vaccine and or unidentified hepatitis B vaccine for prophylaxis. On an unspecified date the subject received unspecified dose of hepatitis B vaccine. According to the legal complaint, at an unspecified time after vaccination with hepatitis B vaccine, the subject experienced serious and permanent neurological injuries which were attributed to toxic mercury exposure. The following information was received via medical records. The subject was vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine on 10/15/96. The subject was also vaccinated with hepatitis B vaccine, HIB vaccine, live attenuated oral poliomyelitis vaccine, and MMR. The subject's family history was significant for two siblings who received speech/language therapy, and an uncle with a history of hearing impairment and developmental delay. The subject began walking at 18 months, described as a little delayed. In 1999, the subject exhibited behaviors including difficulty with change, perservatively arranging objects and staring at them, poor eye contact, inconsistent response to auditory stimuli, and ritualistic behavior. On 4/23/99, the subject was evaluated for significant delay of certain aspects of his physical and mental development. The subject exhibited restlessness and was difficult to control. Testing revealed normal hearing. In May 1999, the subject was examined for concerns including speech and language delays. He was noted to have good interactions with adults and children, and speech therapy was initiated. Assessment of cognitive functioning in October 1999 revealed a significant delay. Assessment included multiple development delays and behaviors consistent with autism. Subsequent reevaluation revealed developmental regression, particularly in expressive language skills. Other deficiencies included adaptive, communication, and social skills. On 1/5/00, the subject's mother contacted his physician and reported that he had been diagnosed with autism. The subject scored 47.5 or severely autistic on the Childhood Autism Rating Scale. On approximately 3/9/00, the subject was diagnosed with encephalopathy. During the 2000-2001 school year, the subject was capable of imitating words and whole phrases. In May 2002, the subject was no longer using understandable words at school. The subject reportedly had never used understandable words at home. Observation included poor motor control for sound production and inability to imitate oral motor movements. On 12/4/04, the subject's mother requested speech services for developmental delay/speech delay. This case was assessed to be medically serious (OMIC).